relacorilant (CORT125134) / Corcept Therap 
Welcome,         Profile    Billing    Logout  
 0 Diseases   7 Trials   7 Trials   114 News 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
relacorilant (CORT125134) / Corcept Therap
2022-000662-18: A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Klinikai vizsgálat a nab-paklitaxellel kombinált relacorilanttal (vizsgálati készítmény) petefészek, petevezeték vagy peritoneális rákban szenvedő betegeknél

Ongoing
3
360
Europe
Relacorilant, Abraxane, CORT125134, Nab-paclitaxel, Capsule, soft, Powder for dispersion for infusion, Abraxane
Corcept Therapeutics Incorporated, Corcept Therapeutics Incorporated
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer, Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer, Diseases [C] - Cancer [C04]
 
 
GRADIENT, NCT04308590 / 2019-004956-12: Efficacy and Safety of Relacorilant in Patients with Cortisol-Secreting Adrenal Adenomas

Active, not recruiting
3
137
Europe, US, RoW
relacorilant, Placebo
Corcept Therapeutics
Hypercortisolism
10/24
10/24
GRACE, NCT03697109 / 2018-003096-35: A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Completed
3
152
Europe, Canada, US, RoW
Relacorilant, CORT125134, Placebo
Corcept Therapeutics
Cushing Syndrome
04/24
04/24
ROSELLA, NCT05257408 / 2022-000662-18: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Active, not recruiting
3
360
Europe, Canada, US, RoW
Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2
Corcept Therapeutics, Gynecologic Oncology Group
Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
12/24
12/25
NCT03776812: Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
2
178
Europe, Canada, US
Relacorilant, 100mg QD, CORT125134, Nab-paclitaxel, 80mg/m^2, Abraxane, Nab-paclitaxel, 100mg/m^2, Relacorilant, 150mg QD
Corcept Therapeutics
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/23
03/23
2018-004186-14: A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer

Not yet recruiting
2
177
Europe
Relacorilant, Abraxane, CORT125134, Nab-paclitaxel, Capsule, hard, Capsule, soft, Powder for suspension for injection, Abraxane
Corcept Therapeutics Incorporated, Corcept Therapeutics Incorporated
Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Diseases [C] - Cancer [C04]
 
 
NCT03604198 / 2018-001616-30: Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Active, not recruiting
2
125
Europe, Canada, US, RoW
relacorilant, CORT125134
Corcept Therapeutics
Cushing Syndrome
12/25
12/25
IRB22-1318, NCT05726292: A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Recruiting
2
90
US
Relacorilant, Enzalutamide, Xtandi, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
University of Chicago
Prostate Cancer, Prostate Adenocarcinoma
10/25
04/29
NCT06094712: A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Completed
1
8
US
CORT125134
Corcept Therapeutics
Healthy
04/16
04/16
NCT06094790: A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Completed
1
32
US
CORT125134 150 mg, CORT125134 250 mg, CORT125134 dose to be determined
Corcept Therapeutics
Healthy
11/17
11/17
NCT06094738: A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Completed
1
30
US
Relacorilant under fasted conditions, CORT125134, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal
Corcept Therapeutics
Healthy
11/20
11/20
NCT06094725: A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Completed
1
30
US
Relacorilant, CORT125134
Corcept Therapeutics
Hepatic Impairment
12/20
12/20
NCT05347979: Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Completed
1
30
US
Dabigatran Etexilate, Pradaxa®, Relacorilant
Corcept Therapeutics
Cushing Syndrome, Neoplasms
07/22
07/22
NCT04373265: Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Completed
1
15
US
Relacorilant, CORT125134, Pembrolizumab, Keytruda
Corcept Therapeutics
Adrenocortical Carcinoma
10/23
01/24
NCT03674814: Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Active, not recruiting
1
35
US
Enzalutamide, Xtandi(R), Relacorilant, CORT-125134
University of Chicago, Corcept Therapeutics, National Cancer Institute (NCI)
Prostate Cancer
01/26
03/26

Download Options